These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9723425

  • 1. Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
    Glanemann M, Langrehr JM, Raakow R, Guckelberger O, Lohmann R, Klupp J, Lobeck H, Schlag H, Keck H, Bechstein WO, Settmacher U, Neuhaus P.
    Transplant Proc; 1998 Aug; 30(5):2159-60. PubMed ID: 9723425
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, Lohmann R, Knoop M, Lobeck H, Schlag H, Keck H, Settmacher U, Bechstein WO, Neuhaus PJ.
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial comparing anti-interleukin-2 receptor antibody and placebo for immunosuppressive therapy after OLT.
    Langrehr JM, Glanemann M, Schneller A, Neumann U, Guckelberger O, Lohmann R, Klupp J, Jonas S, Knoop M, Lobeck H, Schlag H, Keck H, Settmacher U, Bechstein WO, Neuhaus PJ.
    Transplant Proc; 1998 Jun; 30(4):1445-6. PubMed ID: 9636586
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
    Otto G, Hofmann WJ, Gaweco AS, Seelos R, Herfarth C, Meuer S.
    Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
    [No Abstract] [Full Text] [Related]

  • 7. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy.
    Neuhaus B, Keck H, Bechstein WO, Blumhardt G, Langrehr JM, Wiens M, Lemmens HP, Lohmann R, Schlag H, Thalmann U.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):587-9. PubMed ID: 8438426
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
    Nashan B, Schlitt HJ, Schwinzer R, Ringe B, Kuse E, Tusch G, Wonigeit K, Pichlmayr R.
    Transplantation; 1996 Feb 27; 61(4):546-54. PubMed ID: 8610379
    [Abstract] [Full Text] [Related]

  • 10. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation.
    Langrehr JM, Schneller A, Guckelberger O, Lohmann R, Neumann U, Jonas S, Klupp J, Settmacher U, Knoop M, Bechstein WO, Neuhaus PJ.
    Transplant Proc; 1998 Jun 27; 30(4):1439-40. PubMed ID: 9636583
    [No Abstract] [Full Text] [Related]

  • 11. Impact of primary immunosuppression on the incidence of infectious complications after orthotopic liver transplantation.
    Lohmann R, Langrehr JM, Raakow R, Jonas S, Klupp J, Steinmüller T, Neuhaus R, Neuhaus P.
    Transplant Proc; 2000 Nov 27; 32(7):2229-30. PubMed ID: 11120145
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
    van Gelder T, Zietse R, Yzermans JN, Rischen-Vos J, Vaessen LM, Weimar W.
    Transplant Proc; 1996 Dec 27; 28(6):3221-2. PubMed ID: 8962247
    [No Abstract] [Full Text] [Related]

  • 14. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation.
    Lohmann R, Langrehr JM, Klupp J, Neumann U, Guckelberger O, Müller AR, Nüssler NC, Jonas S, Lang M, Settmacher U, Bechstein WO, Neuhaus PJ.
    Transplant Proc; 1999 Dec 27; 31(1-2):380. PubMed ID: 10083151
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
    Lemmens HP, Langrehr JM, Blumhardt G, Lohmann R, Knoop M, Verschl J, Schattenfroh N, Neuhaus R, Hopf U, Bechstein WO.
    Transplant Proc; 1994 Dec 27; 26(6):3622-3. PubMed ID: 7527983
    [No Abstract] [Full Text] [Related]

  • 17. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation.
    Langrehr JM, Lohmann R, Guckelberger O, Müller AR, Raakow R, Nüssler NC, Klupp J, Pfitzmann R, Jonas S, Settmacher U, Steinmüller T, Neuhaus P.
    Transplant Proc; 2001 Dec 27; 33(1-2):1433-4. PubMed ID: 11267360
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis.
    Langrehr JM, Lemmens HP, Keck H, Lohmann R, Knoop M, Neumann U, Müller AR, Platz KP, Kling N, Hopf U.
    Transplant Proc; 1995 Feb 27; 27(1):1215-6. PubMed ID: 7533373
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.